التركيز السريري

منشورات مختارة

• ADIYAMAN S, ALACACIOIGLU İ, Danyeli A, Turkyilmaz D, Sevindik O, Demirkan F, et al. Prognostic factors in elderly patients with diffuse large B-cell lymphoma and their treatment results. Turkish Journal of Hematology. 2019;36(2).
• Akkus E, Tuncalı T, Akın HY, Aydın Y, Beşışışık SK, Gürkan E, et al. Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance cases. British Journal of Haematology. 2024;204(3):931-8.
• Aksoy A, Artas G, Sevindik OG. القيمة الافتراضية لـ (ستاثمين-1) و(أوستيوبونتين) للتعبير عن مقاومة الضريبة في سرطان البروستات المميت Pakistan journal of medical sciences. 2017;33(3):560.
• Alacacioglu I, Medeni SS, Ozsan GH, Payzin B, Sevindik OG, Acar C, et al. هل نظام بي إف إم ممكن لمعالجة سرطان الدم الرئوي الحاد للبالغين؟ A retrospective analysis of the outcomes of BFM and hyper-CVAD chemotherapy in two centers. Chemotherapy. 2015;60(4):219-23.
• Alacacioglu I, Turkyilmaz D, Medeni SS, Acar C, Sevindik O, Piskin O, et al., editors. هل يؤثر إعادة دمج منتجات الخلايا الجذعية في عدة أيام على التكريم؟ BONE MARROW TRANSPLANTATION; 2015: NATURE PUBLISHING GROUP MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND.
• Askin AE, Bektas S, Serin I, Mutlu YG, Aydin BB, Sevindik OG. Germline CEBPA Mutation as a Rare Cause of Chronic Neutropenia. Indian Journal of Hematology and blood Transfusion. 2024:1-4.
• Atas U, Karakus V, Tekin IB, Aydin O, Sevindik OG, Undar L. Obinutuzumab interference with immunoelectrophoresis in a case of follicular lymphoma. International Journal of Laboratory Hematology. 2024.
• Aykaş F, Karakuş V, Sevindik ÖG. النجاح في استخدام الجرعة المجزأة في الدراتومب في مريض متعدد الأورام وزنه زائداً بعد أن كانت الجرعة الأولى تهدد برد الفعل المتصل بالتشريد. Clinical Lymphoma, Myeloma ' Leukemia. 2022.
• Aykaş F, Karakuş V, Sevindik ÖG. النجاح في استخدام الدراتومب المتباعد الجرعة المقسمة في مريض متعدد الورم بعد جرعة أولى من ردود الفعل ذات الصلة بالتشرد. Journal of Oncology Pharmacy Practice. 2024;30(2):397-9.
• Balık Aydın B, Mutlu YG, Sevindik ÖG. Persistent polyclonal B-Cell lymphocytosis with binucleated lymphocytes. Turkish Journal of Hematology. 2021.
• Beköz HS, Sevindik ÖG, Özçelik T, Arat M, Hindilerden IY, Beşıık SK, et al., editors. Comparison of outcomes of total body irradiation (TBI) vs non-TBI conditioning regimens in acute lymphoblsy leukemia for allogeneic transplantation. 45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT); 2019: Nature Publishing Group.
• Beksac M, Tuglular T, Gay F, Mina R, Katodritou E, Unal A, et al. Efficacy of daratumab combined with bortezomib, cyclophosphamide and dexamethasone for the treatment of multiple myeloma patients presenting with extramedullary disease: a European Myeloma Network Study (EMN19). الدم 2022؛140(Supplement 1):10177-9.
• Beksac M, Tuglular T, Gay F, Mina R, Katodritou E, Unal A, et al. P872: EFFICACY of DARATUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE and DEXAMETHASONE IN PATIENTS with MULTIPLE MYELXLXL HemaSphere. 2023;7(S3):e994593a.
• Beksac M, Tuglular T, Gay F, Mina R, Katodritou E, Unal A, et al. Treatment with Daratumab Plus Bortezomib, Cyclophosphamide, and Dexamethasone May Result in Both Hematologic and Metabolic Complete to Achieve Long-Term Progression Freexoma Among Patientu الدم 2023;142:1956.
• Beksac M, Tuglular T, Unal A, Cavo M, Gay F, Katodritou E, et al. Safety of Daratumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic. الدم 2021;138:1657.
• Birtas Atesoglu E, Gulbas Z, Uzay A, Ozcan M, Ozkalemkas F, Dal MS, et al. Glofitamab in relapsed/refractory diffuse large Bcell lymphoma: Real —world data. Hematological oncology. 2023;41(4):663-73.
• Borazan A, Sevindik OG, Solmaz D, Gulcu A, Cavdar C, Sifil A, et al. A rare cause of renovascular hypertension: Takayasu arteritis with only renal artery involvement. فشل الإيجار 2009;31(4):327-31.
• Bozdag S, Seval G, Hindilerden I, Hindilerden F, Andic N, Baydar M, et al. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients. 2022.
• Chatzikonstantinou T, Scarfo L, Demosthenous C, Kotaskova J, Iacoboni G, Minga E, et al. Real-world evidence on therapeutic strategies and treatment-sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CL. الدم 2021؛138(Supplement 1):2635-.
• Ciftciler R, Sevindik O, Tekgunduz A, Erkurt M, Vural F, Turgut B, et al. Acute Lymphoblastic Leukemia in Routine Practice: A Turkish Multicenter. 2019.